Eyepoint Faces Setback as Amylyx Celebrates Success

The pharmaceutical landscape is seeing both challenges and triumphs. Eyepoint has announced disappointing results from its Phase 3 clinical trial for Duravyu, a treatment aimed at age-related blindness. Patients receiving this experimental therapy struggled to maintain their vision compared to those on standard treatment, leading to a significant drop in Eyepoint's stock prices.

In contrast, Ocular Therapeutix, which is developing a competing treatment, saw its shares rise following the news. Meanwhile, Novartis has decided against seeking reimbursement for its newly approved kidney disease drug, Vanrafia, in Canada, citing a complicated access environment that often hampers the availability of new medications.

Source: www.statnews.com